β-Fuoxymorphamine is an opioid acting at μ-opioid receptors. It is used experimentally.[1][2]
Names | |
---|---|
IUPAC name
Methyl (2E)-4-{[(5α,6β)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-6-yl]amino}-4-oxo-2-butenoate
| |
Identifiers | |
3D model (JSmol)
|
|
Abbreviations | β-FOA |
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C22H26N2O6 | |
Molar mass | 414.458 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
See also
editReferences
edit- ^ Portoghese PS, Takemori AE (October 1983). "Different receptor sites mediate opioid agonism and antagonism". Journal of Medicinal Chemistry. 26 (10): 1341–3. doi:10.1021/jm00364a001. PMID 6312042.
- ^ Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, et al. (August 2015). "Structural insights into µ-opioid receptor activation". Nature. 524 (7565): 315–21. Bibcode:2015Natur.524..315H. doi:10.1038/nature14886. PMC 4639397. PMID 26245379.